Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
Novartis submission schedule
Supplementary indications for existing brands
Company overview
Financial review
Conclusions
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Abbreviations
References
Existing brands
INNOVATION
CRM
Immunology
Neuroscience
Oncology
Non-core TA project
2024
LutatheraⓇ
177 Lu-oxodotreotide¹
GEP-NET 1L G2/G3 (EU only)
PluvictoⓇ
AAA617
mCRPC, Pre-taxane
ScemblixⓇ
asciminib
CML 1L
2025
Cosentyx®
secukinumab, AIN457
GCA
LeqvioⓇ
KJX839
Ped Hyperlipidemia
PluvictoⓇ
AAA617
MHSPC2
ZolgensmaⓇ
AVXS-101 OAV101
SMA IT
2026
Cosentyx®
Secukinumab
Polymyalgia rheumatica
RydaptⓇ
midostaurin
Acute myeloid leukemia, pediatrics
ScemblixⓇ
asciminib
CML, 2L, pediatrics
AimovigⓇ
Erenumab
Pediatric Migraine
Cosentyx®
Secukinumab
Tendinopathy
KesimptaⓇ 3
Ofatumumab
Multiple sclerosis, pediatrics
LeqvioⓇ
KJX839
CVRR-LDLC
≥2027
LeqvioⓇ
KJX839
Primary prevention
Mayzent® 2
siponimod
Multiple sclerosis, pediatrics
Piqray/Vijoice®
BYL719
Lymphatic malformations
PluvictoⓇ
AAA617
Oligometastatic PC
CoartemⓇ
artemether + lumefantrine, COA566
Malaria uncompl., formula for <5kg
1. 177 Lu-dotatate in US.
BeovuⓇ
brolucizumab, RTH258
Diabetic retinopathy
Adakveo
SEG101
Sickle cell disease, pediatrics
2. Event-driven trial endpoint. 3. Kesimpta and Mayzent: Pediatric trial in multiple sclerosis run in conjunction (NEOS).
□ NOVARTIS | Reimagining Medicine.
AtecturaⓇ
indacaterol + mometasone, QMF149
Asthma, pediatrics
PromactaⓇ
eltrombopag, ETB115
Radiation sickness syndrome
Novartis Q4 Results | January 31, 2024
43View entire presentation